Lasmiditan: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lasmiditan. Educational only — not medical advice.
Labeled uses
REYVOW® is indicated for the acute treatment of migraine with or without aura in adults.
Source: FDA labeling via NIH DailyMed (set aea3358c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.